Increased tumour angiogenesis in SOX11-positive mantle cell lymphoma.
SOX11
angiogenesis
mantle cell lymphoma
prognosis
Journal
Histopathology
ISSN: 1365-2559
Titre abrégé: Histopathology
Pays: England
ID NLM: 7704136
Informations de publication
Date de publication:
Nov 2019
Nov 2019
Historique:
received:
11
03
2019
accepted:
07
06
2019
pubmed:
8
6
2019
medline:
27
2
2020
entrez:
8
6
2019
Statut:
ppublish
Résumé
Mantle cell lymphoma (MCL) is a heterogeneous disease with an aggressive behaviour in most cases, which is associated with expression of sex determining region-Y-box11 (SOX11). Experimental studies have shown that SOX11 expression is associated with an angiogenic switch characterised by increased expression of angiogenic-related signatures and vascularisation of murine tumours. However, the relationship between angiogenesis and SOX11 expression in primary tumours is not well understood. Therefore, the aim of this study was to evaluate the development of microvascular angiogenesis in primary MCL in relation to SOX11 expression and its potential prognostic value. Fifty-six patients diagnosed with MCL, 38 SOX11-positive and 18 SOX11-negative, were studied. The relative intratumoral microvascular area (MVA) and microvessel density (MVD) (number of intratumoral microvessels/μm These findings suggest that SOX11 promotes an angiogenic phenotype in primary MCL, which may contribute to the more aggressive behaviour of these tumours.
Substances chimiques
SOX11 protein, human
0
SOXC Transcription Factors
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
704-714Subventions
Organisme : Hellenic Haematology Society Foundation
Organisme : Colciencias (Colombian Department of Science, Technology and Innovation) from Government of Colombia
ID : 728-2015
Organisme : Ministerio de Economía y Competitividad
ID : SAF2015-64885-R
Organisme : Instituto de Salud Carlos III
Organisme : Red Temática de Investigación Cooperativa en Cáncer (RTICC)
ID : RD12/0036/0036
Organisme : European Regional Development Fund
Organisme : 'Institució Catalana de Recerca i Estudis Avançats' (ICREA)
Organisme : Generalitat de Catalunya
Organisme : Fondo de Investigación Sanitaria
ID : PI14/00333
Organisme : FEDER
Informations de copyright
© 2019 John Wiley & Sons Ltd.
Références
Swerdlow SH, Campo E, Seto M et al. Mantle cell lymphoma. In Swerdlow SH, Campo E, Harris NL et al. eds. WHO classification of tumours of haematopoietic and lymphoid tissues, revised 4th ed. Lyon, France: IARC Press, 2017; 285-290.
Veloza L, Ribera-Cortada I, Campo E. Mantle cell lymphoma pathology update in the 2016 WHO classification. Ann. Lymph. 2019; 3; 3.
Bea S, Amador V. Role of SOX11 and genetic events cooperating with cyclin D1 in mantle cell lymphoma. Curr. Oncol. Rep. 2017; 19; 43.
Royo C, Navarro A, Clot G et al. Non-nodal type of mantle cell lymphoma is a specific biological and clinical subgroup of the disease. Leukemia 2012; 26; 1895-1898.
Espinet B, Ferrer A, Bellosillo B et al. Distinction between asymptomatic monoclonal B-cell lymphocytosis with cyclin D1 overexpression and mantle cell lymphoma: from molecular profiling to flow cytometry. Clin. Cancer Res. 2014; 20; 1007-1019.
Dictor M, Ek S, Sundberg M et al. Strong lymphoid nuclear expression of SOX11 transcription factor defines lymphoblastic neoplasms, mantle cell lymphoma and Burkitt’s lymphoma. Haematologica 2009; 94; 1563-1568.
Mozos A, Royo C, Hartmann E et al. SOX11 expression is highly specific for mantle cell lymphoma and identifies the cyclin D1-negative subtype. Haematologica 2009; 94; 1555-1562.
Clot G, Jares P, Gine E et al. A gene signature that distinguishes conventional and leukemic nonnodal mantle cell lymphoma helps predict outcome. Blood 2018; 132; 413-422.
Vegliante MC, Palomero J, Perez-Galan P et al. SOX11 regulates PAX5 expression and blocks terminal B-cell differentiation in aggressive mantle cell lymphoma. Blood 2013; 121; 2175-2185.
Kuo PY, Jatiani SS, Rahman AH et al. SOX11 augments BCR signaling to drive MCL-like tumor development. Blood 2018; 131; 2247-2255.
Palomero J, Vegliante MC, Rodriguez ML et al. SOX11 promotes tumor angiogenesis through transcriptional regulation of PDGFA in mantle cell lymphoma. Blood 2014; 124; 2235-2247.
Balsas P, Palomero J, Eguileor A et al. SOX11 promotes tumor protective microenvironment interactions through CXCR12 and FAK regulation in mantle cell lymphoma. Blood 2017; 130; 501-513.
Gratzinger D, Zhao S, Tibshirani RJ et al. Prognostic significance of VEGF, VEGF receptors, and microvessel density in diffuse large B cell lymphoma treated with anthracycline-based chemotherapy. Lab. Invest. 2008; 88; 38-47.
Cardesa-Salzmann TM, Colomo L, Gutierrez G et al. High microvessel density determines a poor outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus chemotherapy. Haematologica 2011; 96; 996-1001.
Jorgensen JM, Sorensen FB, Bendix K et al. Angiogenesis in non-Hodgkin’s lymphoma: clinico-pathological correlations and prognostic significance in specific subtypes. Leuk. Lymph. 2007; 48; 584-595.
Kumar S, Gertz MA, Dispenzieri A et al. Prognostic value of bone marrow angiogenesis in patients with multiple myeloma undergoing high-dose therapy. Bone Marrow Transplant. 2004; 34; 235-239.
Vesela P, Tonar Z, Salek D et al. Microvessel density of mantle cell lymphoma. A retrospective study of its prognostic role and the correlation with the Ki-67 and the mantle cell lymphoma international prognostic index in 177 cases. Virchows Arch. 2014; 465; 587-597.
Tzankov A, Heiss S, Ebner S et al. Angiogenesis in nodal B cell lymphomas: a high throughput study. J. Clin. Pathol. 2007; 60; 476-482.
Soldini D, Valera A, Sole C et al. Assessment of SOX11 expression in routine lymphoma tissue sections: characterization of new monoclonal antibodies for diagnosis of mantle cell lymphoma. Am. J. Surg. Pathol. 2014; 38; 86-93.
Nassiri F, Cusimano MD, Scheithauer BW et al. Endoglin (CD105): a review of its role in angiogenesis and tumor diagnosis, progression and therapy. Anticancer Res. 2011; 31; 2283-2290.
Takeda Y, Kazarov AR, Butterfield CE et al. Deletion of tetraspanin Cd151 results in decreased pathologic angiogenesis in vivo and in vitro. Blood 2007; 109; 1524-1532.
Saba NS, Liu D, Herman SE et al. Pathogenic role of B-cell receptor signaling and canonical NF-κB activation in mantle cell lymphoma. Blood 2016; 128; 82-92.
Klapper W, Hoster E, Determann O et al. Ki-67 as a prognostic marker in mantle cell lymphoma-consensus guidelines of the pathology panel of the European MCL Network. J. Hematop. 2009; 2; 103-111.
Ellis LM, Hicklin DJ. VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat. Rev. Cancer 2008; 8; 579-591.
Vermeulen PB, Gasparini G, Fox SB et al. Quantification of angiogenesis in solid human tumours: an international consensus on the methodology and criteria of evaluation. Eur. J. Cancer 1996; 32A; 2474-2484.
Potti A, Ganti AK, Kargas S et al. Immunohistochemical detection of C-kit (CD117) and vascular endothelial growth factor (VEGF) overexpression in mantle cell lymphoma. Anticancer Res. 2002; 22; 2899-2901.
Bernard S, Danglade D, Gardano L et al. Inhibitors of BCR signalling interrupt the survival signal mediated by the micro-environment in mantle cell lymphoma. Int. J. Cancer 2015; 136; 2761-2774.
Baeriswyl V, Christofori G. The angiogenic switch in carcinogenesis. Semin. Cancer Biol. 2009; 19; 329-337.
Bielenberg DR, Zetter BR. The contribution of angiogenesis to the process of metastasis. Cancer J. 2015; 21; 267-273.
Hoster E, Rosenwald A, Berger F et al. Prognostic value of Ki-67 index, cytology, and growth pattern in mantle-cell lymphoma: results from randomized trials of the European Mantle Cell Lymphoma Network. J. Clin. Oncol. 2016; 34; 1386-1394.
Grossfeld GD, Ginsberg DA, Stein JP et al. Thrombospondin-1 expression in bladder cancer: association with p53 alterations, tumor angiogenesis, and tumor progression. J. Natl Cancer Inst. 1997; 89; 219-227.
Zhang J, Lu A, Li L et al. p16 Modulates VEGF expression via its interaction with HIF-1alpha in breast cancer cells. Cancer Invest. 2010; 28; 588-597.
Ditch S, Paull TT. The ATM protein kinase and cellular redox signaling: beyond the DNA damage response. Trends Biochem. Sci. 2012; 37; 15-22.
Bertolini F, Fusetti L, Mancuso P et al. Endostatin, an antiangiogenic drug, induces tumor stabilization after chemotherapy or anti-CD20 therapy in a NOD/SCID mouse model of human high-grade non-Hodgkin lymphoma. Blood 2000; 96; 282-287.
Ruan J, Hajjar K, Rafii S et al. Angiogenesis and antiangiogenic therapy in non-Hodgkin’s lymphoma. Ann. Oncol. 2009; 20; 413-424.